From its beginnings more than 100 years ago as a simple radiographic image of mastectomy tissue specimens to its present status as the gold standard method of breast cancer detection, mammography serves a critical role in detecting a disease that one in every eight women will be diagnosed with in her lifetime.
The turbulent late 1960s were marked by Vietnam protests, Woodstock, and man’s first steps on the Moon. It was also the dawn of the era of colonoscopy, one of the most significant tools we have against colorectal cancer—the third most commonly diagnosed cancer and second leading cause of cancer death in the US.
London-based oncology diagnostics start-up BeamLine Diagnostics is developing a point-of-care (POC) biopsy triaging and stratification system, called Solas. Solas is estimated to reduce the total number of samples within pathology by approximately 50%, alleviating current system stress. In this candid interview, co-Founder & CEO Dr. Liberty Foreman talks about her inspiration and early experiences in founding the company, her current priorities, and what’s next for BeamLine.
Dublin-based start-up, Selio Medical is developing a novel technology to prevent pneumothorax, a common, costly, and sometimes deadly complication of lung biopsy impacting one in three patients. In this candid interview filmed onsite at MedTech Strategist’s Innovation Summit Dublin, Ireland with Analyst Kayleen Brown, Co-founder & CEO Colm McGarvey talks about his inspiration and early experiences in founding the company, his current priorities, and the lessons he has learned.
Fueled by the passion of pioneering physicists, physicians and medtech innovators looking for a way to fight cancer and make an impact on patient survival and quality of life, cutting-edge oncology devices under development today include an implant designed to infuse chemotherapies directly into aggressive pancreatic tumors, and an MRI-safe robotic system for breast biopsy.
San Francisco-based medtech incubator TheraNova and UCSF Surgical Innovations, an initiative launched by the University’s Department of Surgery along with the Department of Bioengineering & Therapeutic Sciences, are partnering to co-develop device technologies that address unmet patient needs. The team’s first project, being developed with Mitchel Berger, MD, Chair of Neurological Surgery and Director of the Brain Tumor Research Center at UCSF, is a device for use in optimizing brain surgery.